ANSBERT GADICKE Insider Trading $TCRR TCR2 THERAPEUTICS INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for ANSBERT GADICKE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ANSBERT GADICKE. ANSBERT GADICKE is 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in CHIASMA, INC ($CHMA) and Director in Radius Health, Inc. ($RDUS) and 10% Owner in Harpoon Therapeutics, Inc. ($HARP) and Director in Allovir, Inc. ($ALVR) and Director in TCR2 THERAPEUTICS INC. ($TCRR) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in iTeos Therapeutics, Inc. ($ITOS) and Director in iTeos Therapeutics, Inc. ($ITOS) and 10% Owner in Repare Therapeutics Inc. ($RPTX) and Director in Cullinan Management, Inc. ($CGEM).
ANSBERT GADICKE in TCR2 THERAPEUTICS INC.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of ANSBERT GADICKE: Director
Holdings: 79,644 shares
Latest Transaction: Feb 21 2019
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of ANSBERT GADICKE in TCR2 THERAPEUTICS INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALVR, CHMA, CGEM, HARP, ITOS, RDUS, RPTX, RIGL, TCRR, HOWL
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 217,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,586,623 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 105,825 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 32,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 57,552 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,174,998 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 13,599,621 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 907,073 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 325,002 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 493,306 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | P | 15.00 | 1,373,333 | 20,599,995 | 1,569,235 | 195.9 K to 1.6 M (+701.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 35,115 | 0 | 386,270 | 351.2 K to 386.3 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 256,163 | 0 | 2,451,844 | 2.2 M to 2.5 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 17,085 | 0 | 163,532 | 146.4 K to 163.5 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 5,247 | 0 | 57,716 | 52.5 K to 57.7 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,291 | 0 | 88,935 | 79.6 K to 88.9 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 351,155 | 0 | 351,155 | 0 to 351.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,195,681 | 0 | 2,195,681 | 0 to 2.2 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 146,447 | 0 | 146,447 | 0 to 146.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 52,469 | 0 | 52,469 | 0 to 52.5 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 79,644 | 0 | 79,644 | 0 to 79.6 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 217,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,586,623 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 105,825 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 32,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 57,552 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,174,998 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 13,599,621 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 907,073 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 325,002 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 493,306 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | P | 15.00 | 1,373,333 | 20,599,995 | 1,569,235 | 195.9 K to 1.6 M (+701.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 35,115 | 0 | 386,270 | 351.2 K to 386.3 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 256,163 | 0 | 2,451,844 | 2.2 M to 2.5 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 17,085 | 0 | 163,532 | 146.4 K to 163.5 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 5,247 | 0 | 57,716 | 52.5 K to 57.7 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,291 | 0 | 88,935 | 79.6 K to 88.9 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 351,155 | 0 | 351,155 | 0 to 351.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,195,681 | 0 | 2,195,681 | 0 to 2.2 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 146,447 | 0 | 146,447 | 0 to 146.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 52,469 | 0 | 52,469 | 0 to 52.5 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 79,644 | 0 | 79,644 | 0 to 79.6 K |
Page: 1